Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $8.7 million.

  • Compass Therapeutics' Accumulated Expenses rose 19780.52% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 19780.52%. This contributed to the annual value of $6.3 million for FY2024, which is 15007.96% up from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Accumulated Expenses is $8.7 million, which was up 19780.52% from $11.0 million recorded in Q2 2025.
  • Compass Therapeutics' Accumulated Expenses' 5-year high stood at $13.2 million during Q1 2025, with a 5-year trough of $1.8 million in Q1 2024.
  • For the 3-year period, Compass Therapeutics' Accumulated Expenses averaged around $6.9 million, with its median value being $7.2 million (2024).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 7970.48% in 2024, then soared by 62804.41% in 2025.
  • Compass Therapeutics' Accumulated Expenses (Quarter) stood at $2.5 million in 2023, then skyrocketed by 150.08% to $6.3 million in 2024, then skyrocketed by 38.13% to $8.7 million in 2025.
  • Its Accumulated Expenses stands at $8.7 million for Q3 2025, versus $11.0 million for Q2 2025 and $13.2 million for Q1 2025.